832 related articles for article (PubMed ID: 23980065)
1. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
Malcovati L; Hellström-Lindberg E; Bowen D; Adès L; Cermak J; Del Cañizo C; Della Porta MG; Fenaux P; Gattermann N; Germing U; Jansen JH; Mittelman M; Mufti G; Platzbecker U; Sanz GF; Selleslag D; Skov-Holm M; Stauder R; Symeonidis A; van de Loosdrecht AA; de Witte T; Cazzola M;
Blood; 2013 Oct; 122(17):2943-64. PubMed ID: 23980065
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
de Witte T; Bowen D; Robin M; Malcovati L; Niederwieser D; Yakoub-Agha I; Mufti GJ; Fenaux P; Sanz G; Martino R; Alessandrino EP; Onida F; Symeonidis A; Passweg J; Kobbe G; Ganser A; Platzbecker U; Finke J; van Gelder M; van de Loosdrecht AA; Ljungman P; Stauder R; Volin L; Deeg HJ; Cutler C; Saber W; Champlin R; Giralt S; Anasetti C; Kröger N
Blood; 2017 Mar; 129(13):1753-1762. PubMed ID: 28096091
[TBL] [Abstract][Full Text] [Related]
3. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
[TBL] [Abstract][Full Text] [Related]
4. [Complete diagnostic work-up provides the rational basis for the most appropriate therapy of myelodysplastic syndromes].
Pane F
Recenti Prog Med; 2014 Mar; 105(3):100-3. PubMed ID: 24675450
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
Cutler C
Hematology Am Soc Hematol Educ Program; 2010; 2010():325-9. PubMed ID: 21239814
[TBL] [Abstract][Full Text] [Related]
6. Flying without a net in MDS.
Sekeres MA
Blood; 2013 Oct; 122(17):2925-6. PubMed ID: 24159163
[TBL] [Abstract][Full Text] [Related]
7. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T
Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676
[TBL] [Abstract][Full Text] [Related]
8. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
Mishra A; Anasetti C
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
[TBL] [Abstract][Full Text] [Related]
9. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
11. Management of older adults with myelodysplastic syndromes (MDS).
Luskin MR; Abel GA
J Geriatr Oncol; 2018 Jul; 9(4):302-307. PubMed ID: 29290596
[TBL] [Abstract][Full Text] [Related]
12. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
13. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
15. A patient-oriented approach to treatment of myelodysplastic syndromes.
Cazzola M; Anderson JE; Ganser A; Hellström-Lindberg E
Haematologica; 1998 Oct; 83(10):910-35. PubMed ID: 9830800
[TBL] [Abstract][Full Text] [Related]
16. The role of hematopoietic cell transplantation as therapy for myelodysplasia.
Appelbaum FR
Best Pract Res Clin Haematol; 2011 Dec; 24(4):541-7. PubMed ID: 22127318
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
18. Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.
Abel GA; Buckstein R
Am Soc Clin Oncol Educ Book; 2016; 35():e337-44. PubMed ID: 27249740
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome.
Shimomura Y; Hara M; Tachibana T; Ohashi K; Sakura T; Fukuda T; Nakazawa H; Iwato K; Kanda Y; Ikeda T; Eto T; Kanda J; Ichinohe T; Atsuta Y; Ishikawa T; Ishiyama K
Br J Haematol; 2019 Jul; 186(1):86-90. PubMed ID: 30941758
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
